about
Randomized Phase III Trial of Retinoic Acid and Arsenic Trioxide Versus Retinoic Acid and Chemotherapy in Patients With Acute Promyelocytic Leukemia: Health-Related Quality-of-Life OutcomesThe added value of propensity score matching when using health-related quality of life reference data.Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease.Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome studyPatient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia.Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: a systematic review.Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study.The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia.Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes.Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes.Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib.Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors.Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes.Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population.Reply to M. Koehler et al.Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy.Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes.Time to improve health-related quality of life outcomes in patients with acute promyelocytic leukemia.Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.Leaving home, family support and intergenerational ties in Italy: Some regional differencesTime for patient reported outcomes assessment in routine hematology practice: the case of chronic myeloid leukemiaEvaluating methodological quality of Prognostic models Including Patient-reported HeAlth outcomes iN oncologY (EPIPHANY): a systematic review protocolDistribution- and anchor-based methods to determine the minimally important difference on patient-reported outcome questionnaires in oncology: a structured reviewClinician-reported symptomatic adverse events in cancer trials: are they concordant with patient-reported outcomes?Propensity score methods and regression adjustment for analysis of nonrandomized studies with health-related quality of life outcomesModeling strategies to improve parameter estimates in prognostic factors analyses with patient-reported outcomes in oncologyHealth-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemiaPatient-reported outcome assessment in acute leukemias: Moving beyond the barriersThe IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS indexPatient-reported outcomes in randomised clinical trials of bladder cancer: an updated systematic reviewValidation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic MalignanciesInclusion of older patients with cancer in randomised controlled trials with patient-reported outcomes: a systematic reviewTime to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic reviewConsistency matters: measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignanciesHealth-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapyPhysical activity and health-related quality of life in multiple myeloma survivors: the PROFILES registry
P50
Q23671265-B6AD038F-54FE-47F9-86FA-44A6D67448F3Q30641845-37A030D7-A564-4B7F-BDD4-91E19141BED9Q33433457-09767469-EF95-48EF-AB3F-F6BDE727C358Q36299053-2557DFCA-3AAD-4B93-967C-3381E2C0ECFCQ37676310-C330F6B4-2C6E-4691-8FAA-DE1F05CC0F93Q38062214-EEB69D60-7E8F-4105-AFE3-138546FC2FC1Q38960280-626ED639-5388-42D9-879A-42AD1F5A0001Q40346616-C61BCCEA-AC5B-41D4-BB3E-68919BD4DC7DQ40788034-3947CD99-C38C-4C0D-9CE7-19C3304AF8AEQ42640570-49F3CD86-724A-4A3D-99EE-E70E92054F16Q43675594-2AF2AFBC-FBFD-438E-BE8B-26F4C54001C3Q43962118-AC719620-4820-4DB7-8D98-BCD8C5FBC6C1Q43984339-4F5F9166-FBD8-4F07-A502-E85A544D262DQ44306071-6B063921-7654-4626-A098-08B24491F48FQ44531714-302FE2C4-45E3-4336-B900-9AD4F29AC852Q45340443-39AD3FF7-C39A-405B-B016-6FC0B091766BQ47195200-F74D0574-3313-423C-A19E-2BED29A6277CQ47943541-2BE32E53-C58D-47CD-A979-3F2C555BACE9Q52677055-F2BA3FC0-7D2E-4C05-BD52-83F59F830385Q58292509-882215EF-5E37-43AD-BAB4-66F2C273D90CQ58564281-9D3A1E77-25B2-4647-A61C-C5836601D25AQ58565431-BFD0BBDA-D343-4406-A696-0C73AF8C0C45Q59789299-BCED309C-14C2-477A-99E0-81056F047AEBQ64114152-FA61A6CB-66FA-482B-A4E2-543724C850A6Q64115721-935C8742-3A18-4C95-A409-0A1BE8B3BC8DQ64118235-F35D9E04-8324-48C3-A388-AFA4ECE38C7DQ64119389-751FBE18-A616-4EF2-A5B6-77EE8725CC8CQ64124985-4D289037-4B5B-42AD-89F7-40C2A12A632AQ89838225-ABEC481C-7509-469B-A182-CFD359F0575FQ90107019-83D388F0-F7A2-4D3C-A458-060D1188D5B1Q91214461-C47BCD5D-24CB-468F-9D0B-8590B3F42914Q91258723-8193F2DB-6976-4544-BAA8-65A8F0AF5D47Q91498691-6FCAE5E8-B915-4EB9-8A8F-D236502FB69EQ91538355-995F42FD-7F13-412C-B389-0BE3A961692BQ93064395-28634084-D6B6-42D3-AADA-6DB5D0BF20C7Q93115778-7A3FECCA-34D8-42BE-8820-E7536CDAEF51
P50
description
researcher
@en
հետազոտող
@hy
name
Francesco Cottone
@ast
Francesco Cottone
@en
Francesco Cottone
@es
Francesco Cottone
@nl
type
label
Francesco Cottone
@ast
Francesco Cottone
@en
Francesco Cottone
@es
Francesco Cottone
@nl
prefLabel
Francesco Cottone
@ast
Francesco Cottone
@en
Francesco Cottone
@es
Francesco Cottone
@nl
P106
P1153
54779534800
P21
P31
P496
0000-0001-6240-8317